Boryung Corporation
Founded in 1963 and listed in 1988, Boryung is a pharmaceutical and CDMO firm built around its antihypertensive drug Kanarb.
As of 2026-10-11, Boryung Corporation has 73 Korean MFDS device approvals, 382 Korean MFDS drug approvals, 47 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureBoryung was founded in 1963 and listed on the KOSPI in 1988 as a pharmaceutical and CDMO company. It manufactures its self-developed antihypertensive drug Kanarb along with products such as Gelfos (antacid), Mensoledam (analgesic), Duricef (antibiotic), and Astrix (antithrombotic), while developing new and improved drugs in hypertension, dyslipidemia, diabetes, CNS, oncology, and renal disease. The company operates two production sites, Ansan Campus and Yesan Campus, and two R&D centers in Seoul and Gwanggyo, Gyeonggi-do, recording consolidated revenue of about KRW 1,017.4 billion and operating profit of about KRW 65.1 billion in 2025.
Products & technology
- GelfosAntacid
- 구심
- 용각산
- CaprilAntihypertensive
- MensoledamAnti-inflammatory analgesic
- DuricefAntibiotic
- AstrixAntithrombotic
- KanarbAntihypertensive (single-agent ARB)
Regulatory approvals
data.go.kr1 Orphan Drug designations · 2023 / 382 Korean MFDS drug approvals · 1966–2026 / 73 Korean MFDS device approvals · 1998–2018
- OrphanBR1018012023-07-18Orphan Drug designation · in development20230119023
- MFDS drugA.D.Mycin Lyophilized Injection 50mg(Doxorubicin Hydrochloride)2026-09-28Drug · Prescription · Approval202602900
- MFDS drugVonob Tablet 10mg2026-08-24Drug · Prescription · Approval202602453
- MFDS drugVonob Tablet 20mg2026-08-24Drug · Prescription · Approval202602454
- MFDS drugTRUEMPA LM XR Tablet 25/5/1000mg2026-06-18Drug · Prescription · Approval202601730
- MFDS drugTRUEMPA LM XR Tablet 10/5/1000mg2026-06-18Drug · Prescription · Approval202601731
- MFDS drugBRedox tab. 15mg2026-05-28Drug · Prescription · Approval202601537
- MFDS drugBRedox tab. 30mg2026-05-28Drug · Prescription · Approval202601538
- MFDS drugBRedox tab. 60mg2026-05-28Drug · Prescription · Approval202601539
- MFDS drugGelfos Double Action Tab.2026-05-28Drug · OTC · Notification202601555
- MFDS drugLzerozet Tablet 1/10mg2026-04-24Drug · Prescription · Approval202601206
- MFDS drugEPO One Prefilled Injection2026-04-10Drug · Prescription · Approval202601025
Show 68 more
- MFDS drugEPO One Prefilled Injection2026-04-10Drug · Prescription · Approval202601026
- MFDS drugEPO One Prefilled Injection2026-04-10Drug · Prescription · Approval202601027
- MFDS drugKanarbzet Tab. 60/20/10mg2026-02-27Drug · Prescription · Approval202600605
- MFDS drugKanarbzet Tab. 60/10/10mg2026-02-27Drug · Prescription · Approval202600606
- MFDS drugKanarbzet Tab. 30/20/10mg2026-02-27Drug · Prescription · Approval202600607
- MFDS drugKanarbzet Tab. 30/10/10mg2026-02-27Drug · Prescription · Approval202600608
- MFDS drugDasakin Tab. 100mg2026-02-27Drug · Prescription · Approval202600609
- MFDS drugDasakin Tab. 80mg2026-02-27Drug · Prescription · Approval202600610
- MFDS drugDasakin Tab. 70mg2026-02-27Drug · Prescription · Approval202600611
- MFDS drugDasakin Tab. 50mg2026-02-27Drug · Prescription · Approval202600612
- MFDS drugDasakin Tab. 20mg2026-02-27Drug · Prescription · Approval202600613
- MFDS drugBRBCART Powder2025-10-10Drug · Prescription · Approval202502625
- MFDS drugTRUEMPAL Tablet 10/5mg(Empagliflozin, Linagliptin)2025-09-10Drug · Prescription · Approval202502393
- MFDS drugTRUEMPAL Tab. 25/5mg(Empagliflozin, Linagliptin)2025-09-09Drug · Prescription · Approval202502389
- MFDS drugEasysant tab. 10/2.5mg2025-06-17Drug · Prescription · Approval202501483
- MFDS drugTRUEMPA M XR Tablet 10/1000mg(Empagliflozin,Metformin)2025-05-29Drug · Prescription · Approval202501339
- MFDS drugTRUEMPA M XR Tablet 25/1000mg(Empagliflozin,Metformin)2025-05-20Drug · Prescription · Approval202501234
- MFDS drugAlimta Solution inj 25mg/mL2025-04-29Drug · Prescription · Approval202501037
- MFDS drugTrudapa Tab. 5mg(Dapagliflozin Bis L-proline)2025-03-31Drug · Prescription · Approval202500734
- MFDS drugTRUDS M XR Tab. 5/50/1000 mg2025-03-27Drug · Prescription · Approval202500712
- MFDS drugLenvanib cap 4mg2025-02-06Drug · Prescription · Approval202500247
- MFDS drugLenvanib cap 10mg2025-02-06Drug · Prescription · Approval202500248
- MFDS drugLenvanib Cap 12mg2025-02-06Drug · Prescription · Approval202500249
- MFDS drugTRUDS M XR Tab. 10/100/1000 mg2025-01-08Drug · Prescription · Approval202500059
- MFDS drugAlimta Inj. 100mg2024-11-22Drug · Prescription · Approval202402765
- MFDS drugAlimta Inj. 500mg2024-11-22Drug · Prescription · Approval202402766
- MFDS drugRegoranib Tablet 40mg(Regorafenib)2024-11-06Drug · Prescription · Approval202402626
- MFDS drugLetrobo Tab. 2.5mg((Letrozole)2024-10-18Drug · Prescription · Approval202402459
- MFDS drugRabetrix Capsule 100/5mg2024-10-18Drug · Prescription · Approval202402464
- MFDS drugPOMALIKIN Capsule 3mg (Pomalidomide)2024-08-09Drug · Prescription · Approval202401934
- MFDS drugPOMALIKIN Capsule 2mg (Pomalidomide)2024-08-09Drug · Prescription · Approval202401935
- MFDS drugPOMALIKIN Capsule 1mg (Pomalidomide)2024-08-09Drug · Prescription · Approval202401936
- MFDS drugPOMALIKIN Capsule 4mg (Pomalidomide)2024-08-09Drug · Prescription · Approval202401937
- MFDS drugMenthom LoxoTop Plaster2024-05-07Drug · OTC · Notification202401099
- MFDS drugTRUDAPAL tablet 10/5mg2024-04-22Drug · Prescription · Approval202400936
- MFDS drugZyprexa Tab. 2.5mg(Olanzapine)2024-03-27Drug · Prescription · Approval202400667
- MFDS drugZyprexa Tab. 5mg2024-03-27Drug · Prescription · Approval202400668
- MFDS drugZyprexa Tab. 10mg(Olanzapine)2024-03-27Drug · Prescription · Approval202400669
- MFDS drugL50 Tab. 10/5mg2024-03-26Drug · Prescription · Approval202400664
- MFDS drugTRULina M XR Tab. 5/1000mg(Linagliptin, Metformin)2024-03-22Drug · Prescription · Approval202400618
- MFDS drugTRULina M XR Tab. 2.5/1000mg(Linagliptin, Metformin)2024-03-22Drug · Prescription · Approval202400619
- MFDS drugBoryung Nicergoline Tab. 30mg2024-02-21Drug · Prescription · Approval202400372
- MFDS drugBreathon prefilled syringe injection(Sugammadex Sodium)2023-11-30Drug · Prescription · Approval202303260
- MFDS drugNaseron pre-filled syringe Inj. 0.3mg(Ramosetron HCl)2023-09-27Drug · Prescription · Approval202302850
- MFDS drugMonteduo Tablet2023-08-30Drug · Prescription · Approval202302552
- MFDS drugTRUBUDDY tablet 10/15mg(Dapagliflozin,Pioglitazone)2023-08-29Drug · Prescription · Approval202302547
- MFDS drugTRUBUDDY tablet 10/30mg(Dapagliflozin,Pioglitazone)2023-08-29Drug · Prescription · Approval202302548
- MFDS drugCebkhan Plus Tab.2023-08-10Drug · Prescription · Approval202302409
- MFDS drugLzerozet Tablet 4/10mg2023-05-25Drug · Prescription · Approval202301673
- MFDS drugLzerozet Tablet 2/10mg2023-05-25Drug · Prescription · Approval202301674
- MFDS drugAkarb tablet 60/40mg2023-02-28Drug · Prescription · Approval202300720
- MFDS drugAkarb tablet 30/40mg2023-02-28Drug · Prescription · Approval202300721
- MFDS drugGemzarliquid Injection(Gemcitabine Hydrochloride)2023-02-14Drug · Prescription · Approval202300554
- MFDS drugTRUDS Tab. 10/100 mg2023-01-26Drug · Prescription · Approval202300342
- MFDS drugTRUSita M XR Tab. 50/750 mg2023-01-02Drug · Prescription · Approval202300020
- MFDS drugTRUSita M Tab. 50/850 mg2022-12-21Drug · Prescription · Approval202204591
- MFDS drugTRUSita M Tab. 50/500 mg2022-12-21Drug · Prescription · Approval202204592
- MFDS drugTRUSita M Tab. 50/1000mg2022-12-21Drug · Prescription · Approval202204593
- MFDS drugNafastar Injection 50milligram2022-09-22Drug · Prescription · Approval202203629
- MFDS drugNafastar Injection 10milligram2022-09-22Drug · Prescription · Approval202203630
- MFDS drugZepzelca Injection2022-09-22Drug · Prescription · Approval202203642
- MFDS drugFinjuve Spray (Finasteride)2022-09-06Drug · Prescription · Approval202203492
- MFDS drugMenthom IbuCool Plaster2022-08-12Drug · OTC · Notification202203274
- MFDS drugLevlikin Capsule 20mg (Lenalidomide)2022-08-11Drug · Prescription · Approval202203255
- MFDS drugInsevel tablet2022-07-18Drug · Prescription · Approval202203027
- MFDS drugDukarb Plus Tab. 60/5/25mg2022-06-10Drug · Prescription · Approval202202455
- MFDS drugTRUSita M XR 50/500mg2022-05-13Drug · Prescription · Approval202202021
- MFDS drugTRUSita M XR 50/1000mg2022-05-13Drug · Prescription · Approval202202022
Showing the 80 most recent of 456 records.
Clinical trials
data.go.kr134 MFDS clinical trial authorisations · 2012–2026 (Phase 1 82 · Bioequivalence 32 · Phase 3 14 · Phase 2 5 · Phase 4 1)
- Phase 1BR36002026-08-06
2 trial sites
- BioequivalenceBR74032026-05-20
2 trial sites
- BioequivalenceBR74032026-05-20
2 trial sites
- Phase 1BR30062026-05-15
1 trial site
- Phase 1BR30062026-05-15
1 trial site
- BioequivalenceBR74022026-04-24
2 trial sites
- Phase 1BR10182026-04-08
1 trial site
- Phase 1BR10182026-03-11
1 trial site
- Phase 1BR1015-A2026-02-10
1 trial site
- Phase 1BR1015-A2026-02-10
1 trial site
- Phase 1BR1015-A2026-01-12
1 trial site
- Phase 1BR1015-A2026-01-12
1 trial site
Show 68 more
- BioequivalenceBR54122025-12-18
2 trial sites
- BioequivalenceBR50022025-09-01
1 trial site
- Phase 2BR14002025-08-27
31 trial sites
- Phase 1BR74032025-07-28
2 trial sites
- Phase 1BR14022025-05-15
1 trial site
- Phase 1BR14022025-05-15
1 trial site
- Phase 1BR30062025-05-12
1 trial site
- Phase 1BR30062025-05-12
1 trial site
- Phase 2BR1018012025-05-07
17 trial sites
- BioequivalenceBR50022025-01-09
2 trial sites
- Phase 1BR74022024-12-09
1 trial site
- Phase 1BR10182024-11-29
1 trial site
- Phase 1BR1015-A2024-11-20
1 trial site
- Phase 1BR1015-A2024-11-20
1 trial site
- BioequivalenceBR54072024-11-20
2 trial sites
- Phase 1BR1015-A2024-11-19
1 trial site
- Phase 1BR1015-A2024-11-19
1 trial site
- BioequivalenceBR90112024-10-30
2 trial sites
- BioequivalenceBR20092024-10-22
2 trial sites
- Phase 1BR10172024-10-21
1 trial site
- Phase 1BR10172024-10-18
1 trial site
- BioequivalenceBR74012024-10-17
2 trial sites
- BioequivalenceBR74012024-10-17
2 trial sites
- Phase 2BR54022024-09-30
25 trial sites
- Phase 1BR50022024-09-02
2 trial sites
- BioequivalenceBR54002024-08-30
2 trial sites
- Phase 1BR14002024-08-27
3 trial sites
- Phase 1BR10192024-08-22
1 trial site
- Phase 1BR34092024-08-21
1 trial site
- Phase 1BR34092024-08-20
1 trial site
- BioequivalenceBR20092024-08-08
2 trial sites
- BioequivalenceBR50012024-07-08
2 trial sites
- BioequivalenceBR20212024-05-02
4 trial sites
- BioequivalenceBR20222024-03-11
9 trial sites
- Phase 1BR20162024-01-26
2 trial sites
- Phase 1BR30052023-12-28
1 trial site
- Phase 1BR30062023-12-28
2 trial sites
- Phase 1BR30062023-12-28
2 trial sites
- Phase 1BR30052023-12-28
1 trial site
- Phase 1BR10192023-11-24
1 trial site
- Phase 3BR10192023-10-30
52 trial sites
- Phase 1BR50012023-10-17
1 trial site
- Phase 1BR50022023-10-17
1 trial site
- Phase 1BR10172023-10-17
1 trial site
- BioequivalenceBR30072023-09-19
1 trial site
- Phase 3BR10182023-09-15
28 trial sites
- BioequivalenceBR20192023-07-18
2 trial sites
- BioequivalenceBR20192023-07-17
2 trial sites
- BioequivalenceBR20132023-06-28
2 trial sites
- Phase 1BR1015-A2023-06-27
1 trial site
- Phase 1BR1015-A2023-06-27
1 trial site
- Phase 1BR20162023-06-23
2 trial sites
- Phase 1BR20152023-06-22
2 trial sites
- Phase 1BR60022023-05-25
2 trial sites
- Phase 1BR60022023-05-24
2 trial sites
- Phase 3BR10172023-04-06
26 trial sites
- Phase 1BR30062023-04-04
1 trial site
- Phase 1BR30052023-03-15
2 trial sites
- Phase 1BR10192023-03-07
1 trial site
- Phase 1BR60012022-12-26
1 trial site
- Phase 1BR30042022-12-14
1 trial site
- Phase 1BR30042022-12-07
1 trial site
- Phase 3BR1015-A2022-08-02
44 trial sites
- Phase 1BR10182022-06-20
1 trial site
- BioequivalenceBR40042022-06-09
2 trial sites
- BioequivalenceBR40032022-06-09
2 trial sites
- BioequivalenceBR90122022-04-29
2 trial sites
- BioequivalenceBR90112022-04-14
2 trial sites
Showing the 80 most recent of 134 records.
Global clinical trials
ClinicalTrials.gov · sponsor-matchedNot yet recruiting · 2026-08 · NCT07685054
Phase 1 · Not yet recruiting · 2026-04 · NCT07421414
Phase 1 · Not yet recruiting · 2026-04 · NCT07421401
Phase 1 · Not yet recruiting · 2026-04 · NCT07421388
Phase 1 · Not yet recruiting · 2026-04 · NCT07421375
Phase 2 · Not yet recruiting · 2026-03 · NCT07373613
Phase 2 · Not yet recruiting · 2026-02 · NCT07180771
Recruiting · 2025-11 · NCT07263178
Recruiting · 2025-10 · NCT07263191
Phase 1 · Recruiting · 2025-07 · NCT07083401
Show 133 more trials
Phase 1 · Recruiting · 2025-07 · NCT07083388
Phase 1 · Recruiting · 2025-06 · NCT07069335
Phase 4 · Recruiting · 2025-06 · NCT06972732
Phase 2 · Recruiting · 2025-05 · NCT06821945
Phase 1 · Completed · 2025-05 · NCT06889012
Phase 1 · Recruiting · 2025-02 · NCT06867497
Phase 1 · Completed · 2025-01 · NCT06744439
Phase 1 · Completed · 2025-01 · NCT06744062
Phase 1 · Completed · 2025-01 · NCT06744426
Phase 1 · Completed · 2025-01 · NCT06744127
Phase 1 · Completed · 2024-12 · NCT06890299
Phase 1 · Completed · 2024-12 · NCT06890286
Phase 1 · Completed · 2024-11 · NCT06879158
Phase 1 · Completed · 2024-11 · NCT06879132
Phase 1 · Completed · 2024-10 · NCT06636877
Recruiting · 2024-09 · NCT06649162
Phase 1 · Completed · 2024-09 · NCT06889064
Recruiting · 2024-07 · NCT06537752
Phase 3 · Unknown · 2024-05 · NCT06220773
Phase 3 · Completed · 2024-04 · NCT06165250
Recruiting · 2024-03 · NCT06314919
Phase 1 · Completed · 2024-03 · NCT06289933
Phase 1 · Completed · 2024-03 · NCT06289920
Phase 1 · Completed · 2024-02 · NCT06226727
Phase 1 · Completed · 2023-12 · NCT06184269
Recruiting · 2023-10 · NCT06126016
Phase 1 · Completed · 2023-09 · NCT06008015
Recruiting · 2023-08 · NCT06021483
Phase 1 · Completed · 2023-08 · NCT06008028
Recruiting · 2023-07 · NCT05970237
Phase 1 · Completed · 2023-07 · NCT05951946
Phase 1 · Completed · 2023-07 · NCT05959486
Phase 3 · Completed · 2023-07 · NCT05930028
Phase 1 · Completed · 2023-07 · NCT05959499
Phase 1 · Completed · 2023-05 · NCT05875259
Completed · 2023-04 · NCT05788718
Phase 1 · Completed · 2023-03 · NCT06165237
Phase 3 · Completed · 2022-11 · NCT05878561
Completed · 2022-09 · NCT05559606
Phase 1 · Completed · 2022-08 · NCT05460364
Recruiting · 2022-06 · NCT05413057
Phase 1 · Completed · 2022-05 · NCT05372380
Phase 1 · Completed · 2022-04 · NCT05411965
Phase 1 · Completed · 2021-10 · NCT05102266
Phase 1 · Completed · 2021-10 · NCT05102903
Completed · 2021-09 · NCT05086549
Completed · 2021-09 · NCT05102305
Phase 1 · Completed · 2021-09 · NCT05068193
Phase 1 · Completed · 2021-08 · NCT05097794
Phase 3 · Completed · 2021-05 · NCT04885712
Phase 1 · Completed · 2021-04 · NCT04889651
Phase 1 · Completed · 2021-03 · NCT04857047
Phase 1 · Completed · 2021-03 · NCT04846998
Completed · 2021-02 · NCT04770454
Completed · 2021-01 · NCT04789980
- A Study to Evaluate Drug-drug Interactions Between BR9006-1 and BR9006-2 in Healthy Male Volunteers.
Phase 1 · Completed · 2020-07 · NCT04485585
Completed · 2020-06 · NCT04545632
Phase 조기 1/1 · Completed · 2020-06 · NCT04462029
Phase 1 · Completed · 2020-04 · NCT04018248
Completed · 2020-04 · NCT04554953
Active not recruiting · 2020-03 · NCT04416490
Completed · 2019-09 · NCT04131686
Phase 3 · Completed · 2019-06 · NCT03991442
Completed · 2018-11 · NCT04151615
Phase 1 · Completed · 2018-10 · NCT03718611
Phase 1 · Completed · 2018-09 · NCT03629067
Phase 1 · Completed · 2018-07 · NCT03609294
Completed · 2018-07 · NCT03649646
Phase 3 · Completed · 2018-01 · NCT03338426
Phase 1 · Completed · 2017-12 · NCT03390465
Phase 3 · Completed · 2017-09 · NCT03654677
Phase 1 · Completed · 2017-08 · NCT03250052
Completed · 2017-08 · NCT03254914
Phase 3 · Completed · 2017-06 · NCT03654664
Phase 3 · Completed · 2017-05 · NCT03156842
Phase 1 · Withdrawn · 2017-05 · NCT03156127
Phase 1 · Completed · 2016-12 · NCT02994745
Completed · 2016-10 · NCT02913794
Phase 1 · Completed · 2016-10 · NCT02920047
Phase 1 · Completed · 2016-08 · NCT02995720
Completed · 2016-07 · NCT03231293
Phase 3 · Completed · 2016-07 · NCT03246555
Phase 1 · Completed · 2016-04 · NCT02759224
Phase 1 · Completed · 2016-03 · NCT02704702
Phase 3 · Completed · 2016-02 · NCT02620306
Phase 1 · Completed · 2016-02 · NCT02920931
Phase 1 · Completed · 2015-09 · NCT02569814
Phase 4 · Completed · 2015-08 · NCT02532569
Phase 1 · Completed · 2015-08 · NCT02566187
Phase 1 · Completed · 2015-08 · NCT02581696
Phase 1 · Completed · 2015-07 · NCT02493738
Phase 4 · Completed · 2015-06 · NCT02495324
Phase 1 · Completed · 2015-03 · NCT02397590
Phase 3 · Completed · 2015-02 · NCT02458183
Phase 1 · Completed · 2015-02 · NCT02397538
Phase 2 · Completed · 2014-10 · NCT02222480
Phase 3 · Completed · 2014-08 · NCT02166814
Completed · 2014-07 · NCT02394392
Phase 1 · Completed · 2014-07 · NCT02205190
Phase 1 · Completed · 2014-07 · NCT02205151
Phase 3 · Completed · 2014-04 · NCT02152306
Phase 1 · Completed · 2013-08 · NCT01921946
Completed · 2013-05 · NCT02385721
Phase 2 · Completed · 2013-05 · NCT01878201
Phase 4 · Completed · 2012-10 · NCT01736488
Phase 1 · Completed · 2012-06 · NCT01671020
Completed · 2012-04 · NCT02022774
Phase 3 · Completed · 2012-04 · NCT01672476
Phase 3 · Completed · 2011-11 · NCT01499368
Phase 2 · Completed · 2011-08 · NCT01518998
Phase 1 · Completed · 2011-07 · NCT01397214
Phase 3 · Completed · 2010-11 · NCT01258673
Phase 3 · Completed · 2010-08 · NCT01150942
Phase 1 · Completed · 2010-06 · NCT01148368
Phase 1 · Completed · 2010-05 · NCT01146938
Phase 3 · Completed · 2010-04 · NCT01135212
Phase 1 · Completed · 2009-10 · NCT01007409
Phase 1 · Completed · 2009-08 · NCT00991783
Phase 1 · Completed · 2009-07 · NCT00991705
Phase 1 · Completed · 2009-07 · NCT00938132
Phase 1 · Completed · 2009-06 · NCT00938197
Phase 1 · Completed · 2009-04 · NCT00938262
Phase 1 · Completed · 2009-03 · NCT00923533
Phase 1 · Completed · 2009-01 · NCT00937534
Phase 3 · Completed · 2008-12 · NCT00922480
Phase 2 · Completed · 2008-12 · NCT00922441
Phase 2 · Completed · 2007-09 · NCT00923611
Phase 4 · Completed · 2006-09 · NCT00386529
Phase 4 · Completed · 2005-07 · NCT00325936
Phase 2 · Completed · 2005-04 · NCT00937651
Phase 3 · Completed · 2005-01 · NCT00325637
Phase 1 · Completed · 2004-01 · NCT01289899
Phase 1 · Completed · 2003-09 · NCT01289886
R&D and key agreements
Source: DART corporate disclosure항암신약(First-in-class) · Oncology · Developing a first-in-class oncology drug candidate.
대사질환 신약 · 대사질환 · Developing a new drug for metabolic disease.
카나브 패밀리 임상연구 · 고혈압 등 만성질환(카나브 단일제·복합제) · Conducting various clinical studies for Kanarb single-agent and combination formulations.
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- Stage-dependent shifts in bacterial communities and nitrogen cycling during Pyropia cultivation on the west coast of Korea.
Marine environmental research · 2026-09 · Kim HR, Kim JH, Kim SY 외 2
- Predicting Functional Prognosis in Supratentorial Stroke Using [¹⁸F]Fluoro-2-deoxy-D-glucose Positron Emission Tomography.
Yonsei medical journal · 2026-09 · Lee JW, Ohn SH, Jang YW 외 3
- Corrigendum to "BVN008, Diphtheria-tetanus-acellular pertussis combined vaccine has no effects on fertility and prenatal and postnatal developmental toxicity in female Sprague-Dawley rats" [Reprod. Toxicol. 126 (2024) 108587].
Reproductive toxicology (Elmsford, N.Y.) · 2024-10 · Lee JY, Lee JA, Lee HK 외 3
- BVN008, Diphtheria-tetanus-acellular pertussis combined vaccine has no effects on fertility and prenatal and postnatal developmental toxicity in female Sprague-Dawley rats.
Reproductive toxicology (Elmsford, N.Y.) · 2024-06 · Lee JY, Lee JA, Lee HK 외 3
- A combination of BR101801 and venetoclax enhances antitumor effect in DLBCL cells via c-Myc/Bcl-2/Mcl-1 triple targeting.
American journal of cancer research · 2023-01 · Jeon B, Lee YJ, Shin J 외 9
- Automated lung tumor segmentation robust to various tumor sizes using a consistency learning-based multi-scale dual-attention network.
Journal of X-ray science and technology · 2023-01 · Lee J, Lee MJ, Kim BS 외 1
- A randomized, double-blind, multicenter, phase III study on the efficacy and safety of a combination treatment involving fimasartan, amlodipine, rosuvastatin in patients with essential hypertension and dyslipidemia who fail to respond adequately to fimasartan monotherapy.
Clinical hypertension · 2022-12 · Jeon ES, Lim SW, Kim SY 외 14
- Comparative efficacy and safety of fimasartan in patients with hypertension: A network meta-analysis of randomized controlled trials.
Journal of clinical hypertension (Greenwich, Conn.) · 2022-08 · Seo SM, Ihm SH, Yi JE 외 2
- Prediction of Two-Year Recurrence-Free Survival in Operable NSCLC Patients Using Radiomic Features from Intra- and Size-Variant Peri-Tumoral Regions on Chest CT Images.
Diagnostics (Basel, Switzerland) · 2022-05 · Lee S, Jung J, Hong H 외 1
- Synthesis of Novel (S)-3-(1-Aminoethyl)-8-pyrimidinyl-2-phenylisoquinolin-1(2H)-ones by Suzuki-Miyaura Coupling and Their Cell Toxicity Activities.
Pharmaceuticals (Basel, Switzerland) · 2022-01 · Choi OK, Sun YH, Lee H 외 3
Show 37 more publications
- Lung tumor segmentation using dual-coupling net with shape prior based on lung and mediastinal window images from chest CT images.
Journal of X-ray science and technology · 2022-01 · Byun S, Jung J, Hong H 외 1
- Diagnosis and Simultaneous Treatment of Musculoskeletal Injury Using H2O2-Triggered Echogenic Antioxidant Polymer Nanoparticles in a Rat Model of Contusion Injury.
Nanomaterials (Basel, Switzerland) · 2021-09 · Kim GW, Song NH, Park MR 외 4
- Identification of BR102910 as a selective fibroblast activation protein (FAP) inhibitor.
Bioorganic & medicinal chemistry letters · 2021-04 · Jung HJ, Nam EH, Park JY 외 2
- Analysis of hair and plasma samples for methotrexate (MTX) and metabolite using high-performance liquid chromatography triple quadrupole mass spectrometry (LC-MS/MS) detection.
Journal of mass spectrometry : JMS · 2021-04 · Kim DH, Yoo YS, Yoo HJ 외 6
- Synergistic radiosensitizing effect of BR101801, a specific DNA-dependent protein kinase inhibitor, in various human solid cancer cells and xenografts.
American journal of cancer research · 2021-01 · Lee JH, Jeon B, Park M 외 6
- Discovery of a novel fibroblast activation protein (FAP) inhibitor, BR103354, with anti-diabetic and anti-steatotic effects.
Scientific reports · 2020-12 · Cho JM, Yang EH, Quan W 외 2
- Discovery of BR102375, a new class of non-TZD PPARγ full agonist for the treatment of type 2 diabetes.
Bioorganic & medicinal chemistry letters · 2019-08 · Choung W, Yang D, Kim H 외 16
- Use of roller compaction and fines recycling process in the preparation of erlotinib hydrochloride tablets.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2019-04 · Hwang KM, Kim SY, Nguyen TT 외 2
- Identification of BR101549 as a lead candidate of non-TZD PPARγ agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR.
Bioorganic & medicinal chemistry letters · 2019-02 · Choung W, Jung HJ, Yang D 외 15
- Discovery of the bifunctional modulator of angiotensin II type 1 receptor (AT1R) and PPARγ derived from the AT1R antagonist, Fimasartan.
Bioorganic & medicinal chemistry letters · 2018-10 · Choung W, Jung HJ, Nam EH 외 12
- Regional Absorption of Fimasartan in the Gastrointestinal Tract by an Improved in situ Absorption Method in Rats.
Pharmaceutics · 2018-10 · Kim TH, Paik SH, Chi YH 외 8
- Safety and efficacy of fimasartan with essential hypertension patients in real world clinical practice: data from a post marketing surveillance in Korea.
Translational and clinical pharmacology · 2018-09 · Han SE, Jeong SH, Kang HJ 외 4
- Role of cytochrome P450 enzymes in fimasartan metabolism in vitro.
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2018-05 · Choi YJ, Lee JY, Ryu CS 외 3
- Clinical characteristics and satisfaction with the fimasartan in Korean hypertensive patients: a prospective, cross-sectional and open-label, 8-week switching study (Kanarb-hypertension epidemiology medication satisfaction study; K-HEMS study).
Clinical hypertension · 2018-01 · Oh DJ, Han SE, Jeong SH 외 2
- Effects of chronic exposure to cefadroxil and cefradine on Daphnia magna and Oryzias latipes.
Chemosphere · 2017-10 · Kim B, Ji K, Kho Y 외 6
- Characterizing the time-course of antihypertensive activity and optimal dose range of fimasartan via mechanism-based population modeling.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2017-09 · Bulitta JB, Paik SH, Chi YH 외 6
- Monoclonal antibodies against autocrine motility factor suppress gastric cancer.
Oncology letters · 2017-06 · Jung HS, Lee SI, Kang SH 외 6
- Production and Purification of Recombinant Glucocerebrosidase in Transgenic Rice Cell Suspension Cultures.
Applied biochemistry and biotechnology · 2017-04 · Nam HJ, Kwon JY, Choi HY 외 3
- Synthesis and biological evaluation of novel 4-hydroxytamoxifen analogs as estrogen-related receptor gamma inverse agonists.
European journal of medicinal chemistry · 2016-09 · Kim J, Chin J, Im CY 외 17
- Placental transfer and mammary excretion of a novel angiotensin receptor blocker fimasartan in rats.
BMC pharmacology & toxicology · 2016-07 · Kim TH, Kim MG, Shin S 외 10
- Absolute bioavailability and pharmacokinetics of the angiotensin II receptor antagonist fimasartan in healthy subjects.
Journal of clinical pharmacology · 2016-05 · Ghim JL, Paik SH, Hasanuzzaman M 외 4
- The Orphan Nuclear Receptor ERRγ Regulates Hepatic CB1 Receptor-Mediated Fibroblast Growth Factor 21 Gene Expression.
PloS one · 2016-01 · Jung YS, Lee JM, Kim DK 외 12
- Characterization of fimasartan metabolites in human liver microsomes and human plasma.
Xenobiotica; the fate of foreign compounds in biological systems · 2016-01 · Lee JY, Choi YJ, Oh SJ 외 9
- An outbreak of joint and cutaneous infections caused by non-tuberculous mycobacteria after corticosteroid injection.
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2015-07 · Jung SY, Kim BG, Kwon D 외 9
- Glycan structure and serum half-life of recombinant CTLA4Ig, an immunosuppressive agent, expressed in suspension-cultured rice cells with coexpression of human β1,4-galactosyltransferase and human CTLA4Ig.
Glycoconjugate journal · 2015-05 · Kang SH, Jung HS, Lee SJ 외 19
- Safety and immunogenicity of a single intramuscular dose of a tetanus-diphtheria toxoid (Td) vaccine (BR-TD-1001) in healthy Korean adult subjects.
Human vaccines & immunotherapeutics · 2015-01 · Hong T, Chung YJ, Kim TY 외 6
- Comparison of the prescribing pattern of bisphosphonate and raloxifene in Korean women with osteoporosis: from a national health insurance claims database.
PloS one · 2015-01 · Kim J, Shin JY, Lee J 외 3
- A Population Pharmacokinetic Analysis of Fimasartan, a Selective Angiotensin II Receptor Antagonist, in Healthy Caucasian Subjects and Korean Patients With Hypertension.
Clinical pharmacology in drug development · 2013-04 · Lee H, Jang IJ, Yu KS 외 2
- Pharmacological characterization of BR-A-657, a highly potent nonpeptide angiotensin II receptor antagonist.
Biological & pharmaceutical bulletin · 2013-01 · Chi YH, Lee JH, Kim JH 외 6
- Fimasartan, a novel angiotensin II receptor antagonist.
Archives of pharmacal research · 2012-07 · Kim JH, Lee JH, Paik SH 외 2
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
American journal of cardiovascular drugs : drugs, devices, and other interventions · 2011-10 · Chi YH, Lee H, Paik SH 외 5
- Production and characterization of long-acting recombinant human albumin-EPO fusion protein expressed in CHO cell.
Protein expression and purification · 2009-12 · Joung CH, Shin JY, Koo JK 외 6
- Immunogenicity and safety of Vi capsular polysaccharide typhoid vaccine in healthy persons in Korea.
Journal of microbiology and biotechnology · 2007-04 · Lim SM, Jung HS, Kim MJ 외 9
- Production and characterization of human CTLA4Ig expressed in transgenic rice cell suspension cultures.
Protein expression and purification · 2007-02 · Lee SJ, Park CI, Park MY 외 7
- Characterization of human cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (hCTLA4Ig) expressed in transgenic rice cell suspension cultures.
Biotechnology letters · 2006-12 · Jung HS, Koo JK, Lee SJ 외 6
- Comparison between of the attenuated BR-Oka and the wild type strain of Varicella Zoster Virus (VZV) on the DNA level.
Archives of pharmacal research · 2000-08 · Lim SM, Song SW, Kim SL 외 3
- Chongmyungtang attenuates kainic acid-induced seizure and mortal effect in the mouse.
Archives of pharmacal research · 1997-08 · Jang KJ, Lee KH, Kim SL 외 6
Patents
KIPRIS · applicant-matchedUS · Published · 2024-05 · Application 18654486
Published · 2024-04 · Application 1020240052387
Published · 2023-11 · Application 1020230167510
Published · 2022-11 · Application 1020247014182
EP · Published · 2022-11 · Application 22890405.8
PCT · Published · 2022-11 · Application PCT/KR2022/017128
Registered · 2022-06 · Application 1020220069822
PCT · Published · 2022-06 · Application PCT/KR2022/008099
PCT · Published · 2022-05 · Application PCT/KR2022/007699
PCT · Published · 2022-05 · Application PCT/KR2022/006838
Show 275 more patents
Withdrawn · 2022-04 · Application 1020220043987
PCT · Published · 2022-02 · Application PCT/KR2022/002310
Withdrawn · 2022-01 · Application 1020220005913
PCT · Published · 2021-12 · Application PCT/KR2021/019670
Withdrawn · 2021-11 · Application 1020210161994
PCT · Published · 2021-11 · Application PCT/KR2021/016749
Registered · 2021-08 · Application 1020210112329
Registered · 2021-06 · Application 1020237003095
US · Published · 2021-06 · Application 18013801
EP · Registered · 2021-06 · Application 21834397.8
PCT · Published · 2021-06 · Application PCT/KR2021/008200
Withdrawn · 2021-06 · Application 1020210070663
Withdrawn · 2021-06 · Application 1020210070939
Rejected · 2021-05 · Application 1020210062652
PCT · Published · 2021-04 · Application PCT/KR2021/004750
PCT · Published · 2021-03 · Application PCT/KR2021/003950
PCT · Published · 2021-03 · Application PCT/KR2021/003717
PCT · Published · 2021-03 · Application PCT/KR2021/003058
Withdrawn · 2021-02 · Application 1020210022197
PCT · Published · 2021-02 · Application PCT/KR2021/001595
Withdrawn · 2020-12 · Application 1020200182801
Registered · 2020-11 · Application 1020200152769
US · Published · 2020-05 · Application 17612740
EP · Published · 2020-05 · Application 20808745.2
PCT · Published · 2020-05 · Application PCT/IB2020/054719
CN · Published · 2020-05 · Application 202080032970.3
CN · Published · 2020-05 · Application 202080046151.4
Withdrawn · 2020-05 · Application 1020217040285
Withdrawn · 2020-05 · Application 1020217040286
US · Published · 2020-05 · Application 17609270
US · Published · 2020-05 · Application 17609289
EP · Published · 2020-05 · Application 20802939.7
EP · Published · 2020-05 · Application 20801783.0
PCT · Published · 2020-05 · Application PCT/IB2020/054365
PCT · Published · 2020-05 · Application PCT/IB2020/054366
Expired · 2020-04 · Application 1020200046833
Registered · 2020-03 · Application 1020200035974
Withdrawn · 2020-03 · Application 1020200031045
Withdrawn · 2020-02 · Application 1020200014828
CN · Published · 2019-12 · Application 201980087258.0
Expired · 2019-12 · Application 1020217024291
PCT · Published · 2019-12 · Application PCT/KR2019/018684
Expired · 2019-12 · Application 1020190174882
Expired · 2019-12 · Application 1020190174881
PCT · Published · 2019-11 · Application PCT/KR2019/015853
PCT · Published · 2019-07 · Application PCT/KR2019/009309
PCT · Published · 2019-07 · Application PCT/KR2019/008609
Registered · 2019-05 · Application 1020190058895
Withdrawn · 2019-05 · Application 1020190054507
Withdrawn · 2019-05 · Application 1020190054506
TW · Registered · 2019-04 · Application 108114949
PCT · Published · 2019-04 · Application PCT/KR2019/005151
CN · Published · 2019-04 · Application 202610389322.2
CN · Published · 2019-04 · Application 201980018249.6
TW · Registered · 2019-04 · Application 108112937
PCT · Published · 2019-04 · Application PCT/KR2019/004415
Expired · 2019-03 · Application 1020190037087
PCT · Published · 2019-01 · Application PCT/KR2019/000850
TW · Published · 2019-01 · Application 108101263
Registered · 2019-01 · Application 1020207012299
TW · Published · 2019-01 · Application 108101074
Rejected · 2019-01 · Application 1020207012298
Registered · 2018-12 · Application 1020180173547
TW · Published · 2018-12 · Application 107144213
Registered · 2018-12 · Application 1020207012297
PCT · Published · 2018-12 · Application PCT/KR2018/015549
TW · Published · 2018-11 · Application 107143010
TW · Published · 2018-11 · Application 107143011
PCT · Published · 2018-11 · Application PCT/KR2018/015103
CN · Published · 2018-11 · Application 201880076540.4
PCT · Published · 2018-11 · Application PCT/KR2018/014995
Expired · 2018-11 · Application 1020180143502
Expired · 2018-07 · Application 1020180088173
Expired · 2018-07 · Application 1020180081325
CN · Published · 2018-05 · Application 201880033119.5
Expired · 2018-04 · Application 1020180050277
Registered · 2018-04 · Application 1020180043360
Expired · 2018-02 · Application 1020180024903
Expired · 2018-01 · Application 1020180007782
Expired · 2017-11 · Application 1020170163608
Registered · 2017-11 · Application 1020170163597
Registered · 2017-11 · Application 1020170163588
Expired · 2017-09 · Application 1020170119494
Expired · 2017-08 · Application 1020170105707
Registered · 2017-05 · Application 1020170062465
Withdrawn · 2017-03 · Application 1020170032526
Expired · 2016-12 · Application 1020160169501
Withdrawn · 2016-11 · Application 1020160158191
Withdrawn · 2016-11 · Application 1020160158208
Registered · 2016-01 · Application 1020160010354
US · Registered · 2016-01 · Application 15548754
PCT · Published · 2016-01 · Application PCT/KR2016/000221
Withdrawn · 2015-11 · Application 1020150166616
CN · Published · 2015-07 · Application 201510426945.4
Withdrawn · 2015-07 · Application 1020150098394
Rejected · 2015-03 · Application 1020150045376
Registered · 2015-02 · Application 1020150018182
Rejected · 2014-10 · Application 1020140149772
Expired · 2014-10 · Application 1020140145475
Registered · 2014-06 · Application 1020140075491
CN · Published · 2014-03 · Application 201910375600.9
CN · Published · 2014-03 · Application 201480015539
US · Registered · 2014-03 · Application 14774927
Registered · 2014-03 · Application 1020140030190
EP · Registered · 2014-03 · Application 14762250.0
CN · Published · 2013-10 · Application 201380063465
EP · Published · 2013-10 · Application 13845572.0
Expired · 2013-10 · Application 1020130119585
Withdrawn · 2013-10 · Application 1020130118792
CN · Published · 2013-04 · Application 201380040573
CN · Published · 2013-04 · Application 201910766865.1
US · Registered · 2013-04 · Application 14411871
EP · Registered · 2013-04 · Application 13809531.0
Expired · 2013-04 · Application 1020130039234
Expired · 2013-02 · Application 1020130011863
Withdrawn · 2013-01 · Application 1020130009101
Registered · 2013-01 · Application 1020130000295
Withdrawn · 2012-11 · Application 1020120129267
Expired · 2012-10 · Application 1020120113848
Registered · 2012-07 · Application 1020120084035
CN · Published · 2012-07 · Application 201280046679
EP · Published · 2012-07 · Application 12816890.3
Expired · 2012-07 · Application 1020120077421
Expired · 2012-07 · Application 1020120074975
Expired · 2012-07 · Application 1020120074033
Registered · 2012-06 · Application 1020120070359
CN · Published · 2012-03 · Application 201280023159
US · Published · 2012-03 · Application 14004755
EP · Published · 2012-03 · Application 12757234.5
Expired · 2011-11 · Application 1020110117089
Registered · 2011-08 · Application 1020110078417
JP · Registered · 2011-08 · Application 26505053
Expired · 2011-07 · Application 1020110074638
Expired · 2011-07 · Application 1020110070567
Expired · 2011-06 · Application 1020110058809
Expired · 2011-03 · Application 1020110023060
Expired · 2011-01 · Application 1020110001843
EP · Published · 2010-04 · Application 10789629.2
Expired · 2010-01 · Application 1020100005945
Expired · 2009-06 · Application 1020090053670
Expired · 2009-05 · Application 1020090045356
Expired · 2009-01 · Application 1020090004257
Rejected · 2008-09 · Application 1020080090298
US · Published · 2008-07 · Application 12668766
PCT · Published · 2008-07 · Application PCT/KR2008/004029
Expired · 2008-05 · Application 2020080006213
PCT · Published · 2007-12 · Application PCT/KR2007/006248
Expired · 2007-11 · Application 1020070118279
Withdrawn · 2007-11 · Application 1020070118598
Rejected · 2007-11 · Application 1020070118280
Rejected · 2007-11 · Application 1020070114360
PCT · Published · 2007-11 · Application PCT/KR2007/005657
Expired · 2007-09 · Application 1020070095146
PCT · Published · 2007-09 · Application PCT/KR2007/004543
Rejected · 2007-08 · Application 1020070084785
Expired · 2007-07 · Application 1020070074945
Expired · 2007-06 · Application 1020070064581
Expired · 2007-04 · Application 1020070036138
Expired · 2006-12 · Application 2020060032787
Expired · 2006-12 · Application 1020060123949
Rejected · 2005-09 · Application 1020050081947
PCT · Published · 2005-05 · Application PCT/KR2005/001582
Rejected · 2004-09 · Application 1020040074390
Rejected · 2004-05 · Application 1020040039180
Expired · 2004-05 · Application 1020040038098
Expired · 2004-03 · Application 2020040008635
Expired · 2004-03 · Application 1020040021234
EP · Registered · 2004-02 · Application 04250684.0
Expired · 2003-09 · Application 1020030067563
Rejected · 2003-03 · Application 1020030015964
Expired · 2003-02 · Application 1020030008871
Expired · 2002-10 · Application 1020020061850
Expired · 2002-07 · Application 1020020044334
Expired · 2002-07 · Application 1020020044333
Expired · 2002-03 · Application 1020020016131
Expired · 2002-03 · Application 1020020016129
EP · Published · 2002-02 · Application 02701735.9
Rejected · 2001-09 · Application 1020010058526
EP · Registered · 2001-09 · Application 01972742.9
Expired · 2001-05 · Application 1020010024696
Expired · 2001-02 · Application 1020010005993
Expired · 2000-08 · Application 2020000023152
Expired · 2000-08 · Application 1020000044631
Expired · 2000-06 · Application 1020000031807
Expired · 2000-05 · Application 1020000024566
Expired · 2000-03 · Application 1020000014875
Expired · 2000-01 · Application 1020000003783
Expired · 1999-07 · Application 1019990028192
Expired · 1999-07 · Application 1019990027797
Rejected · 1999-05 · Application 1019990016260
CN · Published · 1999-04 · Application 99800613
Expired · 1999-04 · Application 1019997011636
EP · Registered · 1999-04 · Application 99916058.3
Expired · 1999-03 · Application 1019990007183
Expired · 1999-02 · Application 1019990004935
Expired · 1999-02 · Application 1019990004002
Expired · 1999-02 · Application 1019990003528
Expired · 1998-05 · Application 1019980016569
Withdrawn · 1998-04 · Application 1019980014821
Expired · 1998-04 · Application 1019980011873
Expired · 1998-03 · Application 1019980008003
Rejected · 1998-02 · Application 1019980002833
Expired · 1997-11 · Application 1019970063663
Expired · 1997-11 · Application 1019970063080
Rejected · 1997-10 · Application 1019970051540
Rejected · 1997-08 · Application 2019970022185
Expired · 1997-06 · Application 1019970023862
US · Registered · 1997-04 · Application 08837275
US · Registered · 1997-04 · Application 08809314
Expired · 1997-04 · Application 1019970015237
Expired · 1997-04 · Application 1019970015236
Rejected · 1997-04 · Application 1019970012925
Rejected · 1997-04 · Application 2019970007070
Expired · 1997-03 · Application 1019970007578
Expired · 1997-02 · Application 1019970003532
Withdrawn · 1997-01 · Application 1019970001360
Rejected · 1996-12 · Application 1019960069000
Expired · 1996-11 · Application 1019960051868
Expired · 1996-10 · Application 1019960050918
Rejected · 1996-10 · Application 1019960046035
Expired · 1996-08 · Application 1019960032405
Expired · 1996-06 · Application 1019960019773
Expired · 1996-04 · Application 1019960011857
Expired · 1996-04 · Application 1019960009956
Rejected · 1996-03 · Application 1019960008994
Expired · 1995-12 · Application 1019950072400
Expired · 1995-11 · Application 1019950044711
EP · Registered · 1995-09 · Application 95931451.9
Rejected · 1995-08 · Application 2019950023339
Expired · 1995-08 · Application 1019950023918
Expired · 1995-05 · Application 1019950010825
Rejected · 1995-01 · Application 1019950001398
EP · Registered · 1994-11 · Application 94308840.1
Rejected · 1994-11 · Application 1019940030092
Expired · 1994-10 · Application 1019940027559
Expired · 1994-08 · Application 1019940018964
Rejected · 1994-06 · Application 1019940014934
Rejected · 1994-04 · Application 1019940007548
Rejected · 1994-02 · Application 1019940003190
TW · Registered · 1994-02 · Application 083101231
Expired · 1994-02 · Application 1019940001972
Expired · 1993-12 · Application 1019930026496
Expired · 1993-11 · Application 1019930024822
Expired · 1993-10 · Application 1019930021051
Expired · 1993-10 · Application 1019930021049
Expired · 1993-10 · Application 1019930021050
Rejected · 1993-08 · Application 1019930015654
Expired · 1993-07 · Application 1019930014825
Expired · 1993-02 · Application 1019930002635
Rejected · 1993-02 · Application 1019930002532
Expired · 1992-12 · Application 1019920025996
Expired · 1992-12 · Application 1019920023834
Expired · 1992-12 · Application 1019920023690
Expired · 1992-01 · Application 1019920000622
Expired · 1991-11 · Application 1019910019709
Expired · 1987-05 · Application 1019870005495
Expired · 1987-05 · Application 1019870005494
Rejected · 1985-12 · Application 1019850009191
Expired · 1985-08 · Application 1019850006039
Rejected · 1985-05 · Application 1019850003106
Expired · 1985-02 · Application 1019850000850
Rejected · 1985-02 · Application 1019850000705
Expired · 1984-12 · Application 1019840008084
Expired · 1984-12 · Application 1019840007754
Rejected · 1984-08 · Application 2019840007862
Expired · 1984-07 · Application 1019840004361
US · Registered · 1984-02 · Application 06577755
Expired · 1983-12 · Application 1019830005991
Expired · 1980-06 · Application 1019800002463
Expired · 1980-04 · Application 1019800001615
Expired · 1976-02 · Application 2019760000720
Expired · 1976-01 · Application 1019760000090
Expired · 1972-09 · Application 2019720005508
Expired · 1971-07 · Application 1019710001061
Expired · 1971-07 · Application 1019710001062
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive1
- OpenAIOAI-SearchBot56
- GoogleGoogleOther5
- PerplexityPerplexityBot2
- AnthropicClaudeBot2
- MicrosoftBingbot1
Measured since Aug 27, 2026 · 5 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Boryung Corporation and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies approved for the same productsPharma & CDMO
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
GC Medical Science Corporation, KOSDAQ-listed since 2014, operates diagnostic reagent, blood glucose, and hemodialysis solution businesses.
Founded 1996, KOSDAQ-listed 2000, InBody makes body composition analyzers via 18 subsidiaries, generating 83% of revenue overseas.
Founded in 1982 and KOSDAQ-listed in 2008, Sewoon Medical manufactures medical aspirators and catheters/tubes.
Founded 1996, listed on KOSDAQ in 2024, OSANG HEALTHCARE develops and sells biochemistry, immunodiagnostic, and molecular IVD products.
Founded in 1995 and listed on KOSDAQ in 2014, Mediana is a hospital medical device maker developing and manufacturing patient monitors and automated external defibrillators under its own brand and via ODM.
SELVAS Healthcare operates the ACCUNIQ medical diagnostic device brand and the HIMS assistive technology device brand.
Dong-A ST, spun off from Dong-A Socio Holdings in 2013 and KOSPI-listed, makes prescription drugs like Growtropin, Stillen, and Bacchus.
KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.
Founded in 2001 and KOSDAQ-listed in 2011, CU Medical Systems makes AEDs and other emergency medical devices.
Founded in 1945, JW Pharmaceutical holds an original drug pipeline including Rivalo and Hemlibra, plus the IV nutrition product Winuf and OTC brand Hwakol.
KOSDAQ-listed holding company making medical devices and biologics including bone graft rhBMP2 and knee implant TKR.
KOSPI-listed in-vitro diagnostics company known for the STANDARD Q antigen/antibody test kits.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition